Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial data – GeekWire


Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks’ lead drug candidate, zanidatamab, in the U.S., Europe and Japan. The new cash builds on a $50 million payment earlier this year and comes after Tuesday’s release of positive clinical data from a phase 2b trial testing zanidatamab as a second-line treatment for HER2-positive biliary tract cancer. The deal buoys Zymeworks after a year that began with a round of layoffs and is paired with the potential for future payments of up to $1.76 billion. Vancouver, B.C.-headquartered Zymeworks bases its R&D operations in Seattle, where it has 86 employees.


Source link

Related posts

Most popular stories on GeekWire for the week of Jan. 15, 2023 – GeekWire

Laura Peterson

Microsoft’s latest solution for hybrid team-building is another social networking app – GeekWire

Laura Peterson

Amazon aims to take Alexa automation to the next level with new ambient home developer kit – GeekWire

Laura Peterson